TY  - GEN
AU  - Matsumoto,Kimihiro
AU  - Takayama,Nobuyuki
AU  - Aisa,Yoshinobu
AU  - Ueno,Hironori
AU  - Hagihara,Masao
AU  - Watanabe,Kentaro
AU  - Nakaya,Aya
AU  - Chen,Kenko
AU  - Shimizu,Takayuki
AU  - Tsukada,Yuiko
AU  - Yamada,Yuji
AU  - Nakazato,Tomonori
AU  - Ishida,Akaru
AU  - Miyakawa,Yoshitaka
AU  - Yokoyama,Kenji
AU  - Nakajima,Hideaki
AU  - Masuda,Yoshihiro
AU  - Yano,Takahiro
AU  - Okamoto,Shinichiro
TI  - A phase II study of bendamustine plus rituximab in Japanese patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma previously treated with rituximab: BRB study
SN  - 1865-3774
PY  - 2016///0212
KW  - Adult
KW  - Aged
KW  - Antineoplastic Agents
KW  - administration & dosage
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - B-Lymphocytes
KW  - drug effects
KW  - Bendamustine Hydrochloride
KW  - adverse effects
KW  - Drug Administration Schedule
KW  - Female
KW  - Humans
KW  - Leukopenia
KW  - chemically induced
KW  - Lymphoma, B-Cell
KW  - drug therapy
KW  - Lymphoma, Mantle-Cell
KW  - Male
KW  - Middle Aged
KW  - Neoplasm Recurrence, Local
KW  - Neutropenia
KW  - Rituximab
KW  - Treatment Outcome
KW  - Young Adult
N1  - Publication Type: Clinical Trial, Phase II; Journal Article
UR  - https://doi.org/10.1007/s12185-015-1767-3
ER  -